artery graft News
-
Healionics Awarded SBIR Contract from DOD to Develop Biointegrated Synthetic Vascular Graft
Healionics Corporation has been awarded a $150,000 Small Business Innovation Research (SBIR) contract from the Department of Defense (DOD) to demonstrate feasibility for an improved vascular graft design. Andrew Marshall, PhD, Healionics’ Chief Technology Officer, is the Principal Investigator for this research project. Titled, “Biointegrated Synthetic Grafts for Vascular ...
By Healionics
-
Xeltis accelerating clinical trial program
Xeltis announced today that is planning to accelerate its clinical trial program for three restorative devices in parallel. CEO Eliane Schutte provided a sneak preview on Xeltis’ plans to an audience of investors and medtech companies at the Medtech and Diagnostics Forum organised by the investment bank Canaccord Genuity Capital Markets. Xeltis currently has three restorative devices in ...
By XELTIS BV
-
Marizyme Announces Approval for DuraGraft in India
Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that its flagship product DuraGraft® is now registered and licensed for import into India through Marizyme's distribution partner Regency Lifesciences. India ...
-
Xeltis receives €15M funding from EIC Accelerator
Xeltis will receive €15 million in funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. The EIC funding comprises €2.5 millions in grants and up to €12.5 millions in equity and will support Xeltis’ clinical trial program for its XABG device, the first-ever restorative Coronary Artery Bypass Graft (CABG). XABG is a restorative, ...
By XELTIS BV
-
XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease
Company closes additional $22.6 million in new financing Proceeds will fund initiation of new clinical trial for lead gene therapy candidate XC001 as adjunctive therapy for patients undergoing coronary artery bypass graft surgery XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs in ...
-
Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera
Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has entered into a supply and distribution agreement with Abdera Financial, Inc., a Chilean based distributor, to distribute Marizyme's DuraGraft® ...
-
Xeltis lands €15 million European financing from EIB
The European Investment Bank (EIB) has signed a €15 million quasi-equity financing agreement with Xeltis. The EIB’s non-dilutive financing will support the acceleration of clinical programmes for three of Xeltis’ revolutionary, restorative devices. The financing is being made available under the European Guarantee Fund (EGF), an EIB Group initiative in partnership with EU Member ...
By XELTIS BV
-
Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress
Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of products to prevent, treat and diagnose diseases of unmet clinical need announced today that results of the GOAL Study (Vienna Heart Center Floridsdorf/PI Dr. Winkler Bernhard) were presented by Dr. Maximillian Y. Emmert (German Heart Center and Charite Universitatsmedizin, Berlin Germany) Friday, ...
-
tiakis receives GLP Certificate from Competent Authority
tiakis BIOTECH AG today announced that the competent Good Laboratory Practice (GLP) Monitoring Authority of the German State of Schleswig-Holstein (State Office for Agriculture, Environment and Rural Areas of the Land Schleswig-Holstein) has performed a GLP inspection resulting in the confirmation that tiakis test site is able to conduct the archiving of documents related to in-house development ...
-
Marizyme, Inc. Appoints Veteran Business Executive Julie Kampf to Board
Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has named veteran business executive Julie Kampf as an Independent Member of its Board of Directors. "Ms. Kampf will provide invaluable guidance as an ...
-
Advanced Bifurcation Systems Announces First Closing of Series A Financing
Advanced Bifurcation Systems, Inc. (ABS), a Livermore, CA-based maker of the ABS System, a proprietary stent delivery system that is specifically designed to efficiently treat coronary bifurcation lesions, is pleased to announce the first closing of an $11 million Series A equity financing. The round was led by Cedars-Sinai, an internationally renowned academic medical center, and by a leading ...
-
Celixir announces US FDA approval of the IND application for cell therapy Heartcell
FDA IND and UK MHRA CTA approval both achieved in H1 2018 Potentially pivotal heart failure trial of up to 250 patients in the UK and US Celixir, a privately owned company discovering and developing life-saving advanced therapies, announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug application (IND) for Heartcel, its immune-modulatory ...
By Celixir plc
-
Celixir Partners with TMC Life Sciences Bhd and Thomson to Change the Standard of Medical Care for Patients in Southeast Asia
Celixir (formerly Cell Therapy Limited) has recently announced a partnership with TMC Life Sciences Bhd (TMCLS) and its associated company, Thomson Medical (Thomson) to accelerate the discovery and development of life-changing and lifealtering regenerative medicines. Under the terms of the Memoranda of Understanding (MOU), Celixir will develop educational programmes to train medical professionals ...
By Celixir plc
-
tiakis (formerly Proteo Biotech AG) Elafin Enters the Clinic For Subcutaneous Use In Pulmonary Arterial Hypertension
tiakis BIOTECH AG today announced the start of the clinical development for the subcutaneous use of tiakis lead investigational drug candidate Elafin (INN: Tiprelestat). The Duke University Early Phase Research Unit initiated the recruitment of healthy individuals for the Phase I clinical trial in the U.S. to assess the safety and tolerability of repeated single doses of Elafin. tiakis research ...
-
CTA approval for potentially pivotal Heartcel Phase IIb trial
Adult heart failure trial to complete in 2020 with potential market entry in 2021 Trial to be conducted at Imperial College London’s Royal Brompton, UK Celixir, a private company discovering and developing lifesaving regenerative medicines, today announced it has received formal clinical trial application (CTA) approval from the Medicines and Healthcare Products Regulatory Agency to ...
By Celixir plc
-
XyloCor Therapeutics Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina
XyloCor Therapeutics today announced it has successfully dosed the first two patients in the EXACT Trial, a Phase 1/2 dose escalation trial evaluating the safety, tolerability and efficacy of its lead candidate XC001 in patients with refractory angina. The trial will enroll patients who are not responding to medication and are unsuitable for coronary artery bypass graft or percutaneous coronary ...
-
Bilirubin, which eliminates inflammation... Bilix, the world`s first drug
Discovered in the 1930s... fail every time Chemicalized by combining with hydrophilic substances “To develop a treatment for reperfusion injury” Since the 1930s, 'bilirubin', which causes jaundice in humans, has been in the limelight as an anti-inflammatory substance. The phenomenon in which rheumatoid arthritis patients get jaundice causes rheumatoid inflammation to disappear when ...
-
Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories
Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of advanced healthcare products to prevent, treat and diagnose diseases of unmet clinical need, announced today that it has received notice of allowance for foundational patent applications for two of its core technologies in several key markets further strengthening the company’s intellectual ...
-
Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve
Xeltis, a clinical-stage company with the most advanced polymer-based restorative cardiovascular devices, today announced that it has started the first-ever pivotal trial for a synthetic restorative pulmonary valve. To date, pediatric patients requiring right ventricular outflow tract (RVOT) reconstruction have been successfully implanted as part of the global, FDA-approved Xplore2/Pivotal study. ...
By XELTIS BV
-
Marizyme is Pleased to Announce the Appointment of David Barthel as CEO
Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the hiring of Mr. David Barthel as the Chief Executive Officer for Marizyme. In his role Mr. Barthel will look to advance the Company’s technology pipeline and stay committed to the commercialization efforts of DuraGraft in Europe and Asia while focusing on the FDA submissions for ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you